A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...
A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...
Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...
A gut microbe has been identified that mimics the effects of Ozempic to mitigate diabetes and obesity. Here's how to take ...
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
Veru said on Monday its experimental drug, in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...
An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...
In a tearful video posted to Instagram, the 30-year-old from Pheonix, Arizona admitted she took the drug after struggling ...
An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback